September 10, 2021 - RECIST 1.1 and iRECIST are core criteria for advanced clinical trials and their use are extremely important in terms of FDA approval. Samira Farough, MD, our Director of Reader Operations, recently discussed the value of RECIST… Read More
August 31, 2021 - Blood Cancer takes many devastating forms, such as Lymphocytic or Myeloid Leukemia or Hodgkin or non-Hodgkin Lymphoma. Through our advanced imaging techniques, we are working with clinical researchers on numerous trials to identify safe and effective… Read More
August 26, 2021 - At Imaging Endpoints, we take cancer personally. We are actively looking for dedicated professionals who share that feeling and have expertise in various fields. Learn more about how you can play an important role and join… Read More
August 24, 2021 - Imaging Endpoints is consistently outperforming industry standards for reading and response time. We offer same-day, 24-hour and 48-hour responses for eligibility reads and 3 to 5-day response for efficacy reads. Learn more about our industry-leading services… Read More
August 19, 2021 - As the largest oncology-focused iCRO, Imaging Endpoints has extensive experience in soft-tissue sarcomas. The company has participated in a large number of multi-national trials, including one of the industry’s largest, performing real-time double reads with adjudication… Read More
Featured Webinar:
Radiologic Analysis of COVID-19 Infection
June 23, 2020
